SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets orphan drug designation for ZYIL1 in treatment of patients with CAPS

21 Mar 2023 Evaluate

Zydus Lifesciences has been granted ‘Orphan Drug Designation’ (ODD) by the United States Food and Drug Administration (USFDA) for ZYIL1, for treatment of patients with Cryopyrin Associated Periodic Syndrome (CAPS). The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States.

ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates. In September 2022, Zydus had announced positive Phase 2 proof-of-concept (POC) study in CAPS patients, and publication of Phase 1 study results in Clinical Pharmacology in Drug Development, supporting the advancement of ZYIL1 into pivotal clinical trials in CAPS patients.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

942.15 -0.40 (-0.04%)
20-Apr-2026 10:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1672.90
Dr. Reddys Lab 1237.65
Cipla 1237.00
Zydus Lifesciences 942.15
Lupin 2332.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×